רוקחות-פרמקולוגיה

ACE inhibitor linked with lower risk of diabetes in high-risk individuals

מתוך medicontext.co.il

WESTPORT, CT (Reuters Health) – The angiotensin-converting enzyme (ACE) inhibitor ramipril appears to slow the development of diabetes in individuals considered to be at high risk, according to Dr. Salim Yusuf and investigators with the Heart Outcomes Prevention Evaluation (HOPE) trial.

Dr. Yusuf, of McMaster University in Hamilton, Canada, and colleagues previously reported results of the HOPE trial that suggested diabetes developed less frequently and diabetes-related complications were curtailed, in patients taking ramipril (see Reuters Health report, January 20, 2000).

In the new study, published in the October 17th issue of the Journal of the American Medical Association, the HOPE investigators focused on the subjects 55 years of age and older who did not have diabetes at baseline. The subjects had evidence of vascular disease, but not of left ventricular dysfunction or heart failure.

A total of 2837 individuals were randomized to receive up to 10 mg/day of ramipril and 2883 were assigned to placebo. Subsequent diagnoses of diabetes were based on HbA1c values higher than 110% of the upper limit of normal for each laboratory that conducted the tests.

After a mean follow-up of 4.5 years, 102 individuals in the ramipril group (3.6%) were diagnosed with diabetes, compared with 155 in the placebo group (5.4%), a significant difference (p < 0.001).

Dr. Yusuf's research team speculates that ACE-inhibitors slow or reverse the decline in beta-cell function. These drugs could also reduce insulin resistance in skeletal muscle, liver or fat cells, the researchers suggest.

The investigators believe the findings could be of "enormous" clinical and public health significance if confirmed. With that in mind, they have begun a prospective Diabetes Reduction Assessment with Ramipril and rosiglitazone Medication (DREAM) trial, which will involve subjects with impaired glucose tolerance.

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר